Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial

Published:2008-05-22 Issue:1 Volume:29 Page:53-57
ISSN:0172-8172
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Al-Rayes H.,Al-Swailem R.,Al-Balawi M.,Al-Dohayan N.,Al-Zaidi S.,Tariq M.

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s00296-008-0606-8.pdf

Reference23 articles.

1. International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behcet’s disease. Lancet 335:1078–1080

2. Tugal-Tutkun J, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behcet’s disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380

3. Atmaca LS, Batioglu F (1994) The efficacy of cyclosporine-A in the treatment of Behcet’s disease. Ophthalmic Surg 25:321–327

4. Ozdal PC, Ortac S, Taskintuna I, Firat E (2002) Long-term therapy with low dose cyclosporine A in ocular Behcet’s disease. Doc Ophthalmol 105:301–312

5. Kaklamani VG, Kaklamani PG (2001) Treatment of Behcet’s disease: an update. Semin Arthritis Rheum 30:299–312

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. γδ T cells in autoimmune uveitis pathogenesis: A promising therapeutic target;Biochemical Pharmacology;2023-07

2. Comparing biologic options for the management of Behcet’s disease-related uveitis;Expert Review of Clinical Immunology;2023-02-15

3. Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study;Frontiers in Medicine;2023-01-20

4. Long-term Experience with Anti-tumor Necrosis factor- α Therapy in the Treatment of Refractory, Non-infectious Intermediate, Posterior, and Panuveitis;Ocular Immunology and Inflammation;2022-12-20

5. Behcet uveitis: Current practice and future perspectives;FRONT MED-LAUSANNE;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3